Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ed Ajootian who wrote (5001)	8/12/2001 8:45:10 PM
From: Biomaven	Read Replies (1) of 10280

Ed, some seasonality to the Albuterol sales There is huge seasonality in SEPR's principle market (pediatric asthma). 3Q is the worst quarter of the year. Once they break into the COPD market the seasonality should lessen a little. loss levels in the next few quarters are very important To my mind these are essentially irrelevant when looking at the long term picture. At this point the losses are being driven by the timing of R&D expenditures. Income should be helped a little by ramping European Clarinex sales and continued strength in worldwide Allegra. I agree that Xopenex should start giving us some good numbers, but not until 4Q and 1Q02. buy back some stock Again I don't agree with you here. They say they have enough cash to reach profitability without selling more stock, but they clearly don't have much margin for error. Why make it even tighter than it is? sold sometime before the end of '02 I sure hope you are wrong. That's just before they should be entering the golden era of sharply rising profits for several years. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next